Global Experience Documentary: Innovation & Investment in China

Global Experience Documentary: Innovation & Investment in China

Informa Exhibitions released the second documentary film in its SupplySide Global Experience film series, underwritten by Rochem International. Heather Granato, vice president of content, and Jon Benninger, vice president, Health & Nutrition Network, Informa Exhibitions, take viewers behind the scenes with three major suppliers in China to explore the investments these companies are making in infrastructure, quality control, regulatory compliance, technology and more to drive product development and raise the quality bar.

Rochem International is the exclusive U.S. distributor for several leading Chinese suppliers, and has its own offices located in Qingdao, China, to further support its efforts to supply the highest quality ingredients. Companies visited included:

Futaste, which was founded in 1991 in Yucheng, China, and is now the Chinese Functional Sugar City, with a focus on production of xylitol and other polyalcohols. Its planned expansion into the Futaste Biotechnology Industrial Park means within the next five years, the company will invest 1.5 billion yuan to scale its production, ultimately producing 600,000 metric tons of sugar alcohols annually. Further, it developed a proprietary technology to produce xylitol from corn cobs, previously considered a waste product.

Yuwang Bio, the leading Chinese producer of non-genetically modified (GM), identity preserved (IP) soy, currently has 350,000 acres of non GM soy plants, which will yield 70,000 metric tons of soy protein. It has developed and patented low-temperature meal and processing technologies, which it uses in its four soy production facilities--two for white flake and two for protein isolate, and holds nine national invention patents and has developed three state-level new products in the soy area. Further, Yuwang was the first company to gain an exemption to FDA's mandatory detention of Chinese protein after the melamine contamination, due in part to its high quality and testing standards.

Tairui Pharmaceutical, founded in 2000 and now a national key high-tech enterprise with more than 3,000 employees and assets of nearly 5 billion RMB. The largest producer of tylosin in the world, and a leading supplier of other veterinary APIs, the company has recently invested in the vitamin B12 market. Beyond its production facilities, Tairui has also built its own power plant and water treatment facilities, and built three sewage treatment stations to ensure compliance with environmental regs; it holds ISO 14000 certification for environmental management.